In response to the escalating crisis of antimicrobial resistance (AMR), there is an urgent need to research and develop novel antibiotics. This study presents the synthesis and assessment of innovative 4-aminoquinoline-benzohydrazide-based molecular hybrids bearing aryl aldehydes (HD1-23) and substituted isatin warheads (HS1-12), characterized using multispectroscopic techniques with high purity confirmed by HRMS. The compounds were evaluated against a panel of clinically relevant antibacterial strains including the Gram-positive Enterococcus faecium, Bacillus subtilis, and Staphylococcus aureus and a Gram-negative Pseudomonas aeruginosa bacterial strain. Preliminary screenings revealed that several test compounds had significant antimicrobial effects, with HD6 standing out as a promising compound. Additionally, HD6 demonstrated impressively low minimum inhibitory concentrations (MICs) in the range of (8–128 μg/mL) against the strains B. subtilis, S. aureus and P. aeruginosa. Upon further confirmation, HD6 not only showed bactericidal properties with low minimum bactericidal concentrations (MBCs) such as (8 μg/mL against B. subtilis) but also displayed a synergistic effect when combined with the standard drug ciprofloxacin (CIP), highlighted by its FICI value of (0.375) against P. aeruginosa, while posing low toxicity risk. Remarkably, HD6 also inhibited a multidrug-resistant (MDR) bacterial strain, marking it as a critical addition to our antimicrobial arsenal. Computation studies were performed to investigate the possible mechanism of action of the most potent hybrid HD6 on biofilm-causing protein (PDB ID: 7C7U). The findings suggested that HD6 exhibits favorable binding free energy, which is supported by the MD simulation studies, presumably responsible for the bacterial growth inhibition. Overall, this study provides a suitable core for further synthetic alterations for their optimization as an antibacterial agent.

Pleomorphic adenoma (PA) is a common benign tumor of the salivary glands, but its occurrence in the minor salivary glands of the upper lip is rare. In the a case report of a 24-year-old female with PA of the minor salivary glands in the upper lip, exhibiting unique histological characteristics such as features resembling schwannoma, keratinization, myxolipomatous, oncocytic, and mucinous traits resembling mucoepidermoid carcinoma. The main symptom of this condition is a gradual painless enlargement of the affected area. Histopathological analysis confirmed the diagnosis of PA. This case highlights the importance of public education in recognizing and treating painless masses. Further research is needed to explore PA’s histological and molecular characteristics to establish prognostic factors such as the risk of recurrence.

Background: This systematic review and metanalysis aimed to summarize the evidence supporting the significance of particular MiRNAs in PrCa progression and to thoroughly examine the body of prior research.Methods: In accordance with the PRISMA guidelines, this review was conducted using a specifically design data extraction protocol and searching several online databases for relevant articles. The protocol was registered in the PROSPERO database (CRD42023428460).Results: 8 studies were ultimately included in this review. MiRNAs significantly reduced PrCa proliferation, with an odds ratio (OR) of 0.28 (95% CI: 0.21–0.39) and a risk ratio (RR) of 0.51 (95% CI: 0.43–0.61), though moderate heterogeneity was observed (I² = 57%). For two studies investigating MiRNAs as biomarkers for predicting metastasis, the pooled OR was 0.60 (95% CI: 0.47–0.76) and the RR was 0.72 (95% CI: 0.62–0.84), both demonstrating significant predictive value with low heterogeneity (I² = 0%).Conclusion: The results emphasize the potential of miRNAs as biomarkers for predicting PrCa metastasis and demonstrate that miRNAs have a discernible effect on PrCa proliferation. However, to improve our comprehension of MiRNA’s function in this condition, additional studies are required to address the limitations and investigate how MiRNA acts in many areas of PrCa.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023428460.